Scarica l'app Stockscreener
3.56
3.26%
-0.12
Dopo l'orario di chiusura:
3.58
0.02
+0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$3.68
Aprire:
$3.65
Volume 24 ore:
1.73M
Relative Volume:
0.31
Capitalizzazione di mercato:
$314.20M
Reddito:
$409.00K
Utile/perdita netta:
$-101.35M
Rapporto P/E:
-2.1707
EPS:
-1.64
Flusso di cassa netto:
$-71.49M
1 W Prestazione:
-4.04%
1M Prestazione:
-0.56%
6M Prestazione:
-40.27%
1 anno Prestazione:
-45.23%
Intervallo 1D:
$3.535
$3.65
Intervallo di 1 settimana:
$3.535
$3.855
Portata 52W:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Nome
Altimmune Inc
Settore
Industria
Telefono
(240) 654-1450
Indirizzo
910 CLOPPER ROAD, GAITHERSBURG, MD
Confronta ALT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.56 | 330.96M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Sell |
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-04-29 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-24 | Iniziato | Goldman | Neutral |
| 2023-03-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-11 | Iniziato | Guggenheim | Buy |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-11-12 | Reiterato | B. Riley Securities | Buy |
| 2020-09-25 | Iniziato | B. Riley FBR | Buy |
| 2020-08-14 | Iniziato | Evercore ISI | Outperform |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-07-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-02-24 | Ripresa | ROTH Capital | Buy |
| 2019-07-19 | Iniziato | ROTH Capital | Buy |
| 2017-10-09 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Altimmune Inc Borsa (ALT) Ultime notizie
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming DeadlinesALT - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, - GlobeNewswire
Investors in Altimmune, Inc. (ALT): Protect Your RightsContact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
Securities Lawsuit Alert: Altimmune, Inc. (ALT)Contact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
Will breakout in Altimmune Inc. lead to full recoveryJuly 2025 Trends & Safe Investment Capital Preservation Plans - Newser
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
What MACD signals say about Altimmune Inc.Quarterly Portfolio Review & Risk Managed Investment Strategies - Newser
ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. - GlobeNewswire
Altimmune, Inc. (ALT) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
Will Altimmune Inc. price bounce be sustainableWeekly Gains Summary & Weekly Breakout Stock Alerts - Newser
Using data models to predict Altimmune Inc. stock movementJuly 2025 Trade Ideas & Verified Entry Point Detection - Newser
Will Altimmune Inc. outperform the marketEarnings Growth Summary & Stepwise Swing Trade Plans - Newser
Is Altimmune Inc. stock bottoming out2025 Year in Review & Risk Controlled Swing Trade Alerts - Newser
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your RightsALT - WV News
Strategies to average down on Altimmune Inc.2025 Sector Review & Stock Portfolio Risk Control - Newser
Class Action Filed Against Altimmune, Inc. (ALT) Over Securities ViolationsContact Levi & Korsinsky Today - Newsfile
Activist Investor Opportunities and Corporate Governance Risks in Altimmune’s Securities Fraud Litigation - AInvest
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - PR Newswire
Wellington Management Group LLP Grows Stock Holdings in Altimmune, Inc. $ALT - Defense World
Altimmune Inc. stock prediction for this weekWeekly Risk Summary & Reliable Volume Spike Trade Alerts - Newser
Securities Fraud Class Action Filed Against Altimmune, Inc. (ALT)Levi & Korsinsky Reminds Investors of October 6, 2025 - ACCESS Newswire
Developing predictive dashboards with Altimmune Inc. dataTake Profit & Expert Curated Trade Setup Alerts - Newser
Identifying reversal signals in Altimmune Inc.2025 Stock Rankings & High Yield Equity Trading Tips - Newser
Will Altimmune Inc. see short term momentumJuly 2025 EndofMonth & Long-Term Safe Investment Ideas - Newser
Can you recover from losses in Altimmune Inc.July 2025 Pullbacks & Expert Verified Movement Alerts - Newser
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Altimmune, Inc. (ALT) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of October 6, 2025 Deadline - ACCESS Newswire
Deutsche Bank AG Raises Position in Altimmune, Inc. $ALT - Defense World
Altimmune, Inc. $ALT Position Cut by Vanguard Group Inc. - Defense World
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class ActionALT - Eastern Progress
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - The National Law Review
Levi & Korsinsky Notifies Altimmune, Inc. (ALT) Shareholders of Class Action Lawsuit and October 6, 2025 Deadline - ACCESS Newswire
Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade) (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. Sued for Securities Law Violations – - GlobeNewswire
Altimmune (ALT) Stock Rises on FDA's Acceptance of Surrogate Endpoint - GuruFocus
Altimmune Inc Azioni (ALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Altimmune Inc Azioni (ALT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):